Silence Therapeutics plc (SLN) Form 10-Q — Aug 10, 2026
Silence Therapeutics reported a Q2 2026 net loss of $12.3 million, or $0.09 per share, roughly half the $27.4 million ($0.19) loss a year earlier, on nil revenue versus $0.2 million in Q2 2025. For the first half of 2026 the net loss narrowed to $27.2 million from $55.9 million, driven mainly by R&D spend falling $20.1 million year over year after zerlasiran Phase 3 readiness work wrapped up in 2025 and headcount was reduced. Cash and cash equivalents rose to $72.1 million at June 30, 2026 from $11.3 million at year-end as $139.4 million of U.S. Treasury bills were redeemed, and management believes current cash funds operations into 2028.
Key figures
- Revenue
- $0.4 million for the six months ended June 30, 2026 (Q2 2026 revenue was nil vs $0.2 million in Q2 2025)
- Guidance
- Cash and cash equivalents of $72.1M are believed sufficient to fund forecasted operating expenses and capital expenditure requirements into 2028
- Revenue Yoy
- flat year over year on a six-month basis ($0.4M vs $0.4M); Q2 down $0.2M
- Total Assets
- 106412000
- Cash Position
- 72054000
- Shares Outstanding
- 141740037
- Revenue Q2 2025
- 224000
- Accumulated Deficit
- 589632000
- Contract Liabilities
- 55218000
- Revenue Six Months 2025
- 366000
- Uk Tax Loss Carryforward
- 248200000
- Ga Expense Six Months 2026
- 11743000
- Rd Expense Six Months 2025
- 38460000
- Rd Expense Six Months 2026
- 18270000
- Total Shareholders Equity
- 38471000
- Weighted Average Shares Q2 2026
- 141709762
Price after filing
Close on the filing date to close N calendar days later (from $11.72). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.